Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

528 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL.
Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. Jain N, et al. Among authors: wierda w. Blood Adv. 2023 May 23;7(10):1958-1966. doi: 10.1182/bloodadvances.2022008790. Blood Adv. 2023. PMID: 36287248 Free PMC article. Clinical Trial.
Immunotherapy of chronic lymphocytic leukemia.
Wierda WG, O'Brien S. Wierda WG, et al. Expert Rev Anticancer Ther. 2001 Jun;1(1):73-83. doi: 10.1586/14737140.1.1.73. Expert Rev Anticancer Ther. 2001. PMID: 12113136 Review.
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Kantarjian HM, et al. Among authors: wierda w. Clin Cancer Res. 2002 Jul;8(7):2167-76. Clin Cancer Res. 2002. PMID: 12114417 Clinical Trial.
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Faderl S, et al. Among authors: wierda w. Blood. 2003 May 1;101(9):3413-5. doi: 10.1182/blood-2002-07-1952. Epub 2003 Jan 9. Blood. 2003. PMID: 12522009 Free article. Clinical Trial.
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM. Cortes JE, et al. Among authors: wierda w. Blood. 2003 May 15;101(10):3794-800. doi: 10.1182/blood-2002-09-2790. Epub 2003 Jan 30. Blood. 2003. PMID: 12560227 Free article. Clinical Trial.
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ. Tsimberidou AM, et al. Among authors: wierda w. Cancer. 2003 Apr 1;97(7):1711-20. doi: 10.1002/cncr.11238. Cancer. 2003. PMID: 12655528 Free article.
528 results